Merck’s Keytruda Gains Two Additional EU Indications for Gynecologic Cancer Treatment
Merck, Sharp & Dohme Inc., known as MSD (NYSE: MRK), has received two additional indication...
WuXi AppTec Reports Q3 2024 Revenues of RMB 10.46 Billion Amid Biosecure Act Challenges
WuXi AppTec Co., Ltd (SHA: 603259), the China-based Contract Development and Manufacturing Organization (CDMO) facing...
Monte Rosa Therapeutics Strikes Licensing Deal with Novartis for VAV1 Degraders
US-based Monte Rosa Therapeutics (NASDAQ: GLUE) has entered into a licensing agreement with Swiss pharmaceutical...
Jiangsu Hengrui Pharmaceuticals Advances Clinical Trials for Cancer Therapies with NMPA Clearance
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received clinical clearance from China’s National Medical...
AstraZeneca’s Fasenra Approved by EU for Eosinophilic Granulomatosis Treatment
UK pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has received marketing approval from the European Commission...
AbbVie Inks $1.4 Billion Deal to Acquire Alzheimer’s Drug Developer Aliada Therapeutics
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a definitive agreement to acquire all...
CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Myasthenia Gravis Clinical Trial
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Eli Lilly’s Ebglyss Shows Positive Results in Phase III Study for Atopic Dermatitis Patients Previously Treated with Dupilumab
Eli Lilly & Co. (NYSE: LLY), a leading U.S. pharmaceutical company, has announced the results...
CANbridge Pharmaceuticals Scales Back US Operations, Focuses on China for R&D and Commercialization
CANbridge Pharmaceuticals Inc., (HKG: 1228), a China-based pharmaceutical company specializing in rare diseases, has announced...
Biogen’s Felzartamab Demonstrates Promising Results in Phase II Study for IgA Nephropathy
Biogen Inc. (NASDAQ: BIIB), a prominent biopharmaceutical company based in the U.S., has announced comprehensive...
Humanwell Healthcare Receives NMPA Approval for Chemically Synthesized Semaglutide Clinical Trial
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a leading healthcare company based in China, has...
RiboX Therapeutics’ Circular RNA Therapy RXRG001 Gets FDA Green Light for Dry Mouth Clinical Trial
RiboX Therapeutics, a Shanghai-based developer of circular RNA (circRNA) therapies, has announced that it has...
AstraZeneca’s Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment
AstraZeneca Inc., (AZ, NASDAQ: AZN), a UK-based pharmaceutical giant, has announced that it has received...
MicuRx Pharmaceuticals’ Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia
MicuRx Pharmaceuticals Inc. (SHA: 688373), a Sino-US pharmaceutical company, has announced the successful completion of...
NMPA’s CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) released a...
Wantai Biological’s P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, announced last...
Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China
The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on...
GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in...
ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered...
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...